토피라메이트를 복용한 간질환자의 삶의 질 평가
Quality of Life Assessment in Epilepsy Patients With Topiramate
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Quality of life is important in epilepsy treatment. We evaluated the effect of topiramate on the quality of life in epilepsy patients and on the characteristics of the clinical features in patients with improved scores on the Quality of Life in Epilepsy Inventory‐10 (QOLIE‐10). Methods: We included 631 adult epilepsy patients, who were followed for 16 weeks. We analyzed the effect of topiramate on QOLIE‐10 score. The patients were classified into those with improved scores (IG) and those whose scores did not improve (NG). We compared each QOLIE‐10 item and their clinical features between the IG and NG groups. Results: All item scores, as well as the total score, improved after topiramate treatment. Comparison of the scores for each item showed that working and social factor differences of both the IG (>0.72) and NG groups (>0.80)were higher than for the other items. Age, gender, seizure onset, topiramate dose, adverse event, education level,employment, and migraine did not differ significantly between the IG and NG groups. The effect on seizure reduction was the most significant among the clinical features (P<0.001). The epilepsy syndrome, etiology, previous antiepileptic drugs (AEDs), and weight changes did not differ significantly between the two groups (P<0.05). Conclusions: Topiramate treatment can influence the quality of life in adult epilepsy patients, and especially work and social factors. Seizure reduction, epilepsy syndrome, etiology, previous AEDs, and weight change may be the most affected clinical factors in patients who have improved quality of life with topiramate.
Abstract
Background: Quality of life is important in epilepsy treatment. We evaluated the effect of topiramate on the quality of life in epilepsy patients and on the characteristics of the clinical features in patients with improved scores on the Quality of Life in Epilepsy Inventory‐10 (QOLIE‐10). Methods: We included 631 adult epilepsy patients, who were followed for 16 weeks. We analyzed the effect of topiramate on QOLIE‐10 score. The patients were classified into those with improved scores (IG) and those whose scores did not improve (NG). We compared each QOLIE‐10 item and their clinical features between the IG and NG groups. Results: All item scores, as well as the total score, improved after topiramate treatment. Comparison of the scores for each item showed that working and social factor differences of both the IG (>0.72) and NG groups (>0.80)were higher than for the other items. Age, gender, seizure onset, topiramate dose, adverse event, education level,employment, and migraine did not differ significantly between the IG and NG groups. The effect on seizure reduction was the most significant among the clinical features (P<0.001). The epilepsy syndrome, etiology, previous antiepileptic drugs (AEDs), and weight changes did not differ significantly between the two groups (P<0.05). Conclusions: Topiramate treatment can influence the quality of life in adult epilepsy patients, and especially work and social factors. Seizure reduction, epilepsy syndrome, etiology, previous AEDs, and weight change may be the most affected clinical factors in patients who have improved quality of life with topiramate.
참고문헌 (26)
- Johnson EK, "The relative impact of anxiety, depression, and clinical seizure features on health-related quality of life in epilepsy", Epilepsia, 45, pp.544~550 (2004)
- Jacoby A, "Impact of epilepsy on employment status: findings from a UK study of people with well-controlled epilepsy", Epilepsy Res, 21, pp.125~132 (1995)
- Jacoby A, "Epilepsy and social identity: the stigma of a chronic neurological disorder", Lancet Neurol, 4, pp.171~178 (2005)
- Choi-Kwon S, "Factors affecting the quality of life in patients with epilepsy in Seoul, South Korea", Acta Neurol Scand, 108, pp.428~434 (2003)
- Lee SA, "What we confront with employment of people with epilepsy in Korea", Epilepsia, 46, pp.57~58 (2005)
- Lee SA, "Korean QoL in Epilepsy Study Group. Factors contributing to the stigma of epilepsy", Seizure, 14, pp.157~163 (2005)
- Ben-Menachem E, "Topiramate monotherapy in the treatment of newly or recently diagnosed epilepsy", Clin Ther, 30, pp.1180~1195 (2008)
- Brandes JL, "Topiramate for migraine prevention: a randomized controlled trial", JAMA, 291, pp.965~973 (2004)
- Silberstein SD, "Topiramate in migraine prevention: evidence-based medicine from clinical trials", Neurol Sci, 25, pp.244~245 (2004)
- Fritz N, "Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy", Epilepsy Behav, 6, pp.373~381 (2005)
- Kowalik A, "Conversion from carbamazepine or oxcarbazepine to topiramate in adolescents and adults with epilepsy", Acta Neurol Scand, 117, pp.159~166 (2008)
- Stefan H, "Epilepsy outcomes in elderly treated with topiramate", Acta Neurol Scand, 118, pp.164~174 (2008)
- Selai CE, "Evaluation of health status in epilepsy using the EQ-5D questionnaire: a prospective, observational, 6-month study of adjunctive therapy with anti-epileptic drugs", Curr Med Res Opin, 21, pp.733~739 (2005)
- Cramer JA, "A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10", Epilepsia, 37, pp.577~582 (1996)
- Arroyo S, "Randomized dose-controlled study of topiramate as first-line therapy in epilepsy", Acta Neurol Scand, 112, pp.214~222 (2005)
- Shorvon SD, "Safety of topiramate: adverse events and relationships to dosing", Epilepsia, 37, pp.18~22 (1996)
- Ben-Menachem E, "Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures", Epilepsia, 37, pp.539~543 (1996)
- Tassinari CA, "Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy", Epilepsia, 37, pp.763~768 (1996)
- Devinsky O, "Therapy for neurobehavioral disorders in epilepsy", Epilepsia, 45, pp.34~40 (2004)
- Guerrini R, "Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting", Seizure, 14, pp.371~380 (2005)
- Sharief M, "Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy", Epilepsy Res, 25, pp.217~224 (1996)
- Lee BI, "Efficacy of topiramate using lower dose and slower dose-titration in refractory partial epilepsies：a multicenter open clinical trial", J Korean Epilep Soc, 5, pp.59~64 (2001)
- Youn SY, "Clinical factors influencing quality of life in patients with epilepsy", J Korean Neurol Assoc, 18, pp.156~161 (2000)
- Bray GA, "A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity", Obes Res, 11, pp.722~733 (2003)
- 서영성, "Topiramate를 복용한 간질환자에서 체중변화", 가정의학회지, 29(1), pp.20~25 (2008), 대한가정의학회
- Wilding J, "OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects", Int J Obes Relat Metab Disord, 28, pp.1399~1410 (2004)